The HRD Decision--Which PARP Inhibitor to Use for Whom and When

Rucaparib, a polyADPribose polymerase inhibitor (PARPi), was approved recently for use in women with high-grade serous ovarian cancer (HGSOC). It is now one of three approved PARPi for use in recurrent ovarian cancer, a family of agents that has changed the HGSOC treatment landscape and outcome. Clin Cancer Res; 23(23); 7155–7. ©2017 AACR.

See related article by Balasubramaniam et al., p. 7165

from #ORL-AlexandrosSfakianakis via ola Kala on Inoreader http://ift.tt/2i8k0jj